ONCOGENEX PHARMACEUTICALS IN's ticker is OGXI and the CUSIP is 68230A106. A total of 68 filers reported holding ONCOGENEX PHARMACEUTICALS IN in Q4 2013. The put-call ratio across all filers is 38.60 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $0 | – | 1,405 | 0.0% | 0.00% | – |
| Q1 2017 | $0 | – | 1,405 | +28000.0% | 0.00% | – |
| Q4 2016 | $0 | – | 5 | 0.0% | 0.00% | – |
| Q3 2016 | $0 | – | 5 | -66.7% | 0.00% | – |
| Q2 2016 | $0 | – | 15 | -95.2% | 0.00% | – |
| Q1 2016 | $0 | – | 310 | +30900.0% | 0.00% | – |
| Q4 2015 | $0 | -100.0% | 1 | -100.0% | 0.00% | – |
| Q3 2015 | $78,000 | -70.7% | 35,351 | -69.1% | 0.00% | – |
| Q2 2015 | $266,000 | +6550.0% | 114,434 | +5180.8% | 0.00% | – |
| Q1 2015 | $4,000 | -95.5% | 2,167 | -94.4% | 0.00% | – |
| Q4 2014 | $88,000 | – | 38,618 | +87668.2% | 0.00% | – |
| Q3 2014 | $0 | -100.0% | 44 | -100.0% | 0.00% | – |
| Q2 2014 | $688,000 | +368.0% | 184,550 | +1362.9% | 0.00% | – |
| Q1 2014 | $147,000 | +539.1% | 12,615 | +344.3% | 0.00% | – |
| Q4 2013 | $23,000 | -89.5% | 2,839 | -88.1% | 0.00% | – |
| Q3 2013 | $220,000 | – | 23,836 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 1,368,500 | $3,134,000 | 0.61% |
| TANG CAPITAL MANAGEMENT LLC | 365,000 | $836,000 | 0.46% |
| Abingworth LLP | 603,740 | $1,352,000 | 0.38% |
| Cheyne Capital Management (UK) LLP | 150,000 | $338,000 | 0.09% |
| Telemetry Investments, L.L.C. | 50,000 | $114,000 | 0.07% |
| Rotella Capital Management, Inc. | 19,473 | $45,000 | 0.04% |
| SABBY MANAGEMENT, LLC | 461,957 | $1,058,000 | 0.03% |
| Nine Chapters Capital Management LLC | 113,700 | $260,000 | 0.02% |
| STONERIDGE INVESTMENT PARTNERS LLC | 49,471 | $113,000 | 0.02% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 87,388 | $200,000 | 0.01% |